Dr. Kleanthous has over 20 years industry experience in the research & development of recombinant live attenuated and subunit-based vaccines against viral and bacterial pathogens.
He joined Sanofi Pasteur as US Head of Discovery Research in 2008 with responsibility for evaluating and developing novel viral vaccine platforms and delivering novel targets to the Development pipeline. Previously, Dr. Kleanthous was Vice President of Research at Acambis Inc. (formerly OraVax) with responsibility for developing a new exploratory portfolio. His research interests are in the field of replication-defective viral vaccine platforms, targeting Influenza, Flaviviruses and Herpes viruses, as well as their use for foreign antigen delivery.
Prior to joining industry, Dr. Kleanthous was a scientific investigator at academic teaching hospitals and the Health Protection Agency in the UK, where he developed his expertise in the area of infectious diseases and molecular epidemiology. He obtained his Ph.D. in the field of Molecular Microbiology from the University of London.